Vitek to develop prion technology:
This article was originally published in Clinica
Executive Summary
US company VI Technologies (Vitex) has entered into two agreements with Oxford University in the UK to develop products for identifying and removing prions from blood. The firm has licensed Oxford's proprietary RNA ligand technology, which is designed to selectively bind to prions. It has also signed an agreement to investigate the basic science of aptamer technology applied to the blood transfusion industry. Currently there are no diagnostic tests for prion-related diseases, says Vitex of Watertown, Massachusetts.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.